Opportunities and challenges in antiparasitic drug discovery

Nature Reviews Drug Discovery

Volumn 4, Issue 9, 2005, Pages 727-740

  Pink, Richard ^a   Hudson, Alan ^a   Mouriès, Marie Annick ^a   Bendig, Mary ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMODIAQUINE; AMPHOTERICIN B LIPID COMPLEX; ANTIMALARIAL AGENT; ANTIMONY DERIVATIVE; ANTIPARASITIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ATOVAQUONE PLUS PROGUANIL; BENZNIDAZOLE; BORRELIDIN; CHALCONE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; DIETHYLCARBAMAZINE; EFLORNITHINE; FANSIDAR; IVERMECTIN; MEFLOQUINE; MELARSOPROL; MILTEFOSINE; MOXIDECTIN; NEW DRUG; NIFURTIMOX; OXAMNIQUINE; PENTAMIDINE; PRAZIQUANTEL; PYRIMETHAMINE; SURAMIN; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL MODEL; BRAIN MALARIA; CHAGAS DISEASE; DISEASE CONTROL; DRUG CONTRAINDICATION; DRUG COST; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INDICATION; DRUG POTENTIATION; DRUG TARGETING; FILARIASIS; HIGH THROUGHPUT SCREENING; HUMAN; LEISHMANIASIS; MALARIA; NONHUMAN; ONCHOCERCIASIS; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SCHISTOSOMIASIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TROPICAL DISEASE; VALIDATION PROCESS; ANIMAL; CHEMISTRY; METHODOLOGY; PHARMACEUTICS;

ANIMALS; ANTIPARASITIC AGENTS; DRUG DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 26044468809     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1824     Document Type: Review

References (110)

1. Trouiller, P. et al. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359, 2188-2194 (2002).
2. Global Forum for Health Research. The 10/90 Report on Health Research, 2003-2004 (Global Forum for Health Research, Geneva, 2004).
3. Médecins Sans Frontières Access to Essential Medicines Campaign. Fatal Imbalance: The crisis in Research and Development for Drugs for Neglected Diseases (Médecins Sans Frontières, Geneva, 2001).
4. Nwaka, S. & Ridley, R. G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919-928 (2003).
5. Kettler, H. E. & Marjanovic, S. Engaging biotechnology companies in the development of innovative solutions for diseases of poverty. Nature Rev Drug Discov. 3, 171-176 (2004).
6. Medicines for Malaria Venture. Annual Report 2002 [online], (2003).
7. Ridley, R. G. Research on infectious diseases requires better coordination. Nature Med. 10 (Suppl.), S137-S140 (2004).
8. Rosenthal, P. J. Antimalarial drug discovery: Old and new approaches. J. Exp. Biol. 206, 3735-3744 (2003).
9. Barry, C. E. III & Duncan K. Tuberculosis - strategies towards anti-infectious for a chronic disease. Drug Discov. Today: Ther. Strat. (in the press).
10. Willcox, M. L. & Bodeker, G. Traditional herbal medicines for malaria. BMJ 329, 1156-1159 (2004).
11. Basu, P. Trading: On traditional medicines. Nature Biotechnol. 22, 263-265 (2004).
12. Mpia, B. & Pepin, J. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop. Med. Int. Health 7, 775-779 (2002).
13. TDR. TDR Sixteenth Programme Report: Progress 2001-2002 [online], (2003).
14. Kremsner, P. G. & Krishna, S. Antimalarial combinations. Lancet 364, 285-294 (2004).
15. Medicines for Malaria Venture. Annual Report 2003 [online], (2004).
16. Yeates, C. DB-289 Immtech International. IDrugs 6, 1086-1093 (2003).
17. Urbina, J. A. & Docampo, R. Specific chemotherapy of Chagas disease:. controversies and advances. Trends Parasitol. 19, 495-501 (2003).
18. Yuvaniyama, J. et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nature Struct. Biol. 10, 357-365 (2003).
19. O'Neill, P. M. et al. Isoquine and related amodiaquine analogues: A new generation of improved 4-aminoquinoline antimalarials. J. Med. Chem. 46, 4933-4945 (2003).
20. Biot, C. et al. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol. Pharm. 2, 185-193 (2005).
21. Cotreau, M. M. et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43, 1108-1115 (2003).
22. Nwaka, S., Riopel, L., Ubben, D. & Craft, J. C. Medicines for Malaria Venture new developments in antimalarials. Travel Med. and Inf. Disease 2, 161-170 (2004).
23. Tagboto, S. & Townson, S. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv. Parasitol. 50, 199-295 (2001).
24. Klayman, D. L. Qinghaosu (artemisinin): An antimalarial drug from China. Science 228, 1049-1055 (1985).
25. Ang, K. K., Holmes, M. J., Higa, T., Hamann, M. T. & Kara, U. A. In vivo antimalarial activity of the β-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. 44, 1645-1649 (2000).
26. Lui, M., Wilairat, P., Croft, S. L., Tan, L. C. A. & Go, M. L. Structure-activity, relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem. 11, 2729-2738 (2003).
27. Otoguro, K. et al. In vitro and in vivo antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of Plasmodia. J. Antibiot. (Tokyo) 56, 727-729 (2003).
28. Maes, L. et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Massa balansae against visceral leishmania species. Antimicrob. Agents Chemother. 48, 130-136 (2004).
29. Yeh, I., Hanekamp, T., Tsoka, S., Karp, P. D. & Altman, R. B. Computational analysis of Plasmodium falciparum metabolism: Organizing genomic information to facilitate drug discovery. Genome Research 14, 917-924 (2004).
30. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
31. Bush, K., Macielag, M. & Weidner-Wells, M. Taking inventory: antibacterial agents currently at or beyond phase 1. Curr. Opin. Microbiol. 7, 466-476 (2004).
32. Overbye, K. M. & Barrett, J. F. Antibiotics: Where did we go wrong? Drug Discov Today 10, 45-52 (2005).
33. Thomson, C. J., Power, E., Ruebsamen-Waigmann, H. & Labischinski, H. Antibacterial research and development in the 21(st) century - an industry perspective of the challenges. Curr. Opin. Microbiol. 7, 445-450 (2004).
34. Gribbon, P. & Sewing, A. High-throughput drug discovery: What can we expect from HTS? Drug Discov. Today 10, 17-22 (2005).
35. Bleicher, K. H., Bohm, H. J., Muller, K. & Alanine, A. I. Hit and lead generation: Beyond high-throughput screening. Nature Rev. Drug Discov. 2, 369-378 (2003).
36. Phillips, M. A., Coffino, P., & Wang, C. C. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei: Implications for enzyme turnover and selective difluoromethylornithine inhibition.. J. Biol. Chem. 262, 8721-8727 (1987).
37. Jones,. A. K., Buckingham, S. D. & Sattelle, D. B. Chemistry-to-gene screens in Caenorhabditis elegans. Nature Rev. Drug Discov. 4, 321-330 (2005).
38. Behm, C. A., Bendig, M. M., McCarter, J. P. & Sluder, A. E. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. 21, 97-100 (2005).
39. Sajid, M. & McKenow, J. H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120, 1-21 (2002).
40. Musonda, C. C. & Chibale, K. Application of combinatorial and parallel synthesis methodologies to antiparasite drug discovery. Curr. Med. Chem. 11, 2519-2533 (2004).
41. Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Antimalarial drug discovery: Efficacy models for compound screening. Nature Rev Drug Discov. 3, 509-520 (2004).
42. Lee, B. J. et al. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother. 47, 3810-3814 (2003).
43. Peters, W., Fleck, S. L., Robinson, B. L., Stewart, L. B. & Jefford, C. W. The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials. Ann. Trop. Med. Parasitol. 96, 559-573 (2002).
44. Vennerstrom, J. L. et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430, 900-904 (2004).
45. Bendig, M. Graduate of the TDR 'malperox' programme reaches the clinics. TDRnews 73, Oct (2004).
46. Widdus, R. Public-private partnerships for health: Their main targets, their diversity, and their future directions. Bull. World Health Organ. 79, 713-720 (2001).
47. Nishtar, S. Public-private 'partnerships' in health - a global call to action. Health Res. Policy Syst. 2, 5 (2004).
48. Webber, D. & Kremer, M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull. World Health Organ. 79, 735-741 (2001).
49. Horton, J. Drug development for tropical diseases - present situation, future perspectives. Trends Parasitol. 19, P06 (2003).
50. Editorial. Africa 2005. Nature 433, 669 (2005).
51. Breman, J. G., Alilio, M. S. & Mills, A. Conquering the intolerable burden of malaria: WhAt's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 71 (2 Suppl.), 1-15 (2004).
52. World Health Organization. The World Health Report 2004 [online], (2004).
53. Burri, C. & Brun, R. Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res. 90 (Supp. 1, S49-S52 (2003).
54. Lell, B. et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother. 47, 735-738 (2003).
55. Jha, T. et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341, 1795-1800 (1999).
56. Medicines for Malaria Venture. Annual Report 2003 [online], (2003).
57. Triglia, T., Meriting, J. G., Wilson, C. & Cowman, A. F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94, 13944-13949 (1997).
58. Hudson, A. T. et al. 566C80: A potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. 17, 427-435 (1991).
59. Looareesuwan, S., Chulay, J. D., Canfield, C. J. & Hutchinson, D. B. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria.
60. Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 60, 533-541 (1999).
61. Fry, M. & Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43, 1545-1553 (1992).
62. Jomaa, H. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285, 1573-1576 (1999).
63. Borrmann, S. et al. Fosmidomycin-clindamycin in Plasmodium falciparum infections in African children. J. Infect. Dis. 189, 901-908 (2004).
64. Kuzoe, F. A. Current situation of African trypanosomiasis. Acta Trop. 54, 153-162 (1993).
65. Urbina J. A., New chemotherapeutic approaches for the treatment of Chagas disease (American trypanosomiasis). Expert Opin. Ther. Patents 13, 661-669 (2003).
66. Buckner, F. et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl Acad Sci. USA 100, 15149-15153 (2003).
67. Martin, M. B. et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: A potential route to chemotherapy. J. Med. Chem. 44, 909-916 (2001).
68. Martin, R. J. Modes of action of anthelmintic drugs. Vet. J. 154, 11-34 (1997).
69. Lacey, E. Mode of action of benzimidazoles. Parasitol. Today, 6, 112-115 (1990).
70. Omura, S. & Crump, A. The life and times of ivermectin - a success story. Nature Rev. Microbiol. 2, 984-989 (2004).
71. Cully, D. F., Wilkinson, H., Vassilatis, D. K., Etter, A. & Arena, J. P. Molecular biology and electrophysiology of glutamate-gated chloride channels of invertebrates. Parasitology 113 (Suppl.) S191-S200 (1996).
72. Baldwin, J. et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280, 21847-21853 (2005).
73. Kemp, L. E., Bond, C. S. & Hunter, W. N. Structure of 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase: An essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development. Proc. Natl Acad. Sci. USA 99, 6591-6596 (2002).
74. Rosenthal, P. J. Cysteine proteases of malaria parasites. Int. J. Parasitol. 34, 1489-1499 (2004).
75. Gelb, M. H. et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126, 155-163 (2003).
76. Ohkanda, J. et al. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J. Med. Chem. 47, 432-445 (2004).
77. Waller, R. F. et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl Acad. Sci. USA 95, 12352-12357 (1998).
78. Morita, Y. S., Paul, K. S. & Englund, P. T. Specialised fatty acid synthesis in African trypanosomes: Myristate for GPI anchors. Science 288, 140-143 (2000).
79. Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med. 7, 167-173 (2001).
80. Meinnel, T. Peptide deformylase of eukaryotic protists: A target for new antiparasitic agents? Parasitol. Today 16, 165-168 (2000).
81. Joet, T. & Krishna, S. The hexose transporter of Plasmodium falciparum is a worthy drug target. Acta Trop. 89, 371-374 (2004).
82. Wyllie, S., Cunningham, M. L., & Fairlamb, A. H. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmana donovani. J. Biol. Chem. 279, 39925-39932 (2004).
83. Saravanamuthu, A. et al. Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: A template for drug design. J. Biol. Chem. 279, 29493-29500 (2004).
84. Daubenberger, C. A. et al. Identification and recombinant expression of glyceraldehyde-3-phosphate dehydrogenase of Plasmodium falcipamm. Gene 246, 255-264 (2000).
85. Kron, M., Petridis, M., Milev, Y., Leykam, J. & Hartlein, M. Expression, localization' and alternative function of cytoplasmic asparaginyl-tRNA synthetase in Brugia malayi. Mol. Biochem. Parasitol. 129, 33-39 (2003).
86. Cameron, A. et al. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J. Biol. Chem. 279, 31429-31439 (2004).
87. Tripathi, A. K. et al. An α-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium falciparum. Cloning and biochemical characterization of the enzyme. Eur. J. Biochem. 271, 3488-3502 (2004).
88. Blackman, M. J. Proteases involved in erythrocyte invasion by the malaria parasite: Function and potential as chemotherapeutic targets. Curr. Drug Targets 1, 59-83 (2000).
89. Doerig, C., Endicott, J. & Chakrabarti, D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasitol. 32, 1575-1585 (2002).
90. Keenan, S. M., Geyer, J. A., Welsh, W. J., Prigge, S. T. & Waters, N. C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin-dependent kinase inhibitors. Comb. Chem. Highthroughput Screen. 8, 27-38 (2005).
91. Kasekarn, W., Sirawaraporn, R., Chahomchuen, T., Cowman, A. F. & Sirawaraporn, W. Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. Mol. Biochem. Parasitol. 137, 43-53 (2004).
92. Fries, D. S. & Fairlamb, A. H. in Burger's Medicinal Chemistry and Drug Discovery Sixth Edn Vol. 5: Chemotherapeutic Agents (ed. Abraham, D. J.) Ch. 15 (J. Wiley & Sons, Chichester, 2003).
93. Fumarola, L., Spinelli, R. & Brandonisio, O. In vitro assays for evaluation of drug activity against Leishmania spp.. Res. Microbiol. 155, 224-230 (2004).
94. Lorente, S. O. et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother 48, 2937-2950 (2004).
95. Raz, B., Iten, M., Grether-Buhler, Y., Kaminsky, R. & Brun, R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 68, 139-147 (1997).
96. Ansede, J. H. et. al. O-alkoxyamidine prodrugs of furamidine: In vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. 47, 4335-4338 (2004).
97. Yardley, V. & Croft, S. L. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. 61, 193-197 (1999).
98. Yan, W., & Moreno, S. N. J. J. Immunol. Methods 220, 123-128 (1998).
99. Urbina, J. A. et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21, 39-48 (2003).
100. Cheever, A. W., Lenzi, J. A., Lenzi, H. L. & Andrade, Z. A. Experimental models of Schistosoma mansoni infection. Mem. Inst. Oswaldo Cruz 97, 917-940 (2002).
101. Liang, Y. S., Coles, G. C., Doenhoff, M. J. & Southgate V. R. In vitro responses of praziquantel-resistant and - susceptible Schistosoma mansoni to praziquantel. Int. J. Parasitol. 31, 1227-1235 (2001).
102. 50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int. J. Parasitol. 34, 979-987 (2004).
103. Utzinger, J., Chollet, J., Tu, Z., Xiao, S. & Tanner, M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected. mice. Trans. R. Soc. Trop. Med. Hyg. 96, 318-323 (2002).
104. Farah, I. O., Kariuki, T. M., King, C. L. & Hau, J. An overview of animal models in experimental schistosomiasis and refinements in the use of non-human primates. Lab. Anim. 35, 205-212 (2001).
105. Townson, S. The development of a laboratory model for onchocerciasis using Onchocerca gutturosa: In vitro culture, collagenase effects, drug studies and cryopreservation. Trop. Med. Parasitol. 39, 475-479 (1988).
106. Suswillo, R. R. and Denham, D. A. A new system for testing for filaricidal activity using transplanted adult Brugia in the jird. J. Parasitol. 63, 591-592 (1977).
107. Court, J. P., Stables, J. N., Lees, G. M., Martin-Short, M. R. & Rankin, R. Dipetalonema viteae and Brugia pahangi transplant infections in gerbils for use in antifilarial screening. J. Helminthol. 62, 1-9 (1988).
108. McCall, J. W., Dzimianski, M. T., Supakorndej, P. & Jun, J. J. The antifilarial activity of moxidectin against patent infections of Brugia pahangi in dogs. Am. J. Trop. Med. Hygiene 61 (Suppl.), 444 (1999).
109. Townson, S., Dobinson, A., Connelly, C. & Muller, R. Chemotherapy of Onchocerca lienalis microfilariae in mice: A model for the evaluation of novel compounds for the treatment of onchocerciasis. J. Helminthol. 62, 181-194 (1988).
110. Strote, G., Weiland, S., Darge, K. & Comley, J. C. W. In vitro assessment of the activity of anthelmintic compounds on adults of Onchocerca volvulus. Acta Liedensia 59, 285-296 (1990).